search
Back to results

Nutritional Supplementation in Sarcopenic Obesity (SARCO)

Primary Purpose

Sarcopenic Obesity

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Diet + protein
Diet + EAA
Diet + EAA and TCA
Diet
Sponsored by
Istituto Auxologico Italiano
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sarcopenic Obesity

Eligibility Criteria

50 Years - 65 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • patients with obesity (BMI> 35kg / m2)
  • sarcopenia (criteria described in Coltorti A et al).

Exclusion Criteria:

  • renal insufficiency
  • diabetes
  • muscular pathologies
  • neurological-neurodegenerative pathologies
  • cognitive decline

Sites / Locations

  • Amelia Brunani

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

Diet Arm

Protein Arm

EAA Arm

EAA + TCA

Arm Description

low-calorie diet normoproteic with an energy deficit of 15% compared to what emerged from the calorimetric value (basal REE)

low-calorie diet normoproteic + an integration of 8.72 g of protein in the form of a nutritional supplement (18-20% protein)

low-calorie diet normoproteic + amino acid supplement (2 sachet/daily; 1 sachet contains protein 0 gr, carbohydrates 6.69 gr , lipids 0 gr, i-leucine 1,2 gr, i-isoleucine 0,6 gr, i-valine 0,6 gr).

low-calorie diet normoproteic + an amino acid supplement (2 stick/daily; 1 stick pack contains protein 0 gr, carbohydrates 1,046 gr, lipids 0.074 gr, i-leucine 1.2 gr, i-isoleucine 0.6 gr, i-valine 0.6 gr, citric acid, succinic acid and malic acid)

Outcomes

Primary Outcome Measures

Change of Body weight
weight in kilograms
Change of Height
height in meters
Change of BMI
weight and height will be combined to report BMI in kg/m^2
Change of Waist
waist circumference in centimeters
Change of FM
Fat Mass (FM) in % of body weight in kilograms
Change of FFM
Free Fat Mass (FFM) in % of body weight in kilograms
Change of MM
Muscle Mass (MM) in % of body weight in kilograms
Change of Muscle strenght
muscle streght at the hand (right and left) in kg
Change of Walking
6 minute walk test (6MWT), meters walking in 6 minutes
Change of TUG
time, in second, to up from the chair, walks 3 meters, turns around, walks back to the chair and sits down
Change of Metabolic profile
glycaemia, total cholesterol, LDL cholesterol, triglycerides all in mg/dl
Change of Insulin secretion
insulin pasma levels in mU/l
Change of Homa index
glycaemia and insulin will be combined to report Homa index in mmol/l/mU/l
Change of Muscle function
irisin and procollagen type III N-terminal peptide (P3NP) in ng/ml
Change of Muscle wasting
C-terminal agrin fragment (CAF) in pg/ml

Secondary Outcome Measures

Full Information

First Posted
November 10, 2021
Last Updated
November 22, 2021
Sponsor
Istituto Auxologico Italiano
search

1. Study Identification

Unique Protocol Identification Number
NCT05143398
Brief Title
Nutritional Supplementation in Sarcopenic Obesity
Acronym
SARCO
Official Title
Effectiveness of a Rehabilitation Program (Nutritional + Physical Activity) in Sarcopenic Obesity
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
September 1, 2018 (Actual)
Primary Completion Date
October 15, 2020 (Actual)
Study Completion Date
March 10, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Istituto Auxologico Italiano

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The obese patient presents a quantitative and qualitative deficit of muscle mass as occurs in the elderly subject that was named Sarcopenic Obesity (SO). The use of a diet that includes protein supplements and / or essential amino acids seems to improve this condition in the elderly; there are no similar studies in obese subjects, in particular during a low-calorie diet and physical activity program that can produce further loss of muscle mass. This study aims to verify whether the administration of these supplements (protein or amino acid) in the obese patient are effective in improving anthropometric and functional parameters and some serum markers of muscle metabolism. The results obtained could represent new therapeutic protocols in the treatment of obesity.
Detailed Description
Several studies have confirmed that adequate nutrition, especially protein intake, including at breakfast, or supplementation with amino acids, in association with adequate physical activity plays an important role in the treatment of SO. The supplementation of protein or amino acid preparations (in particular with the 9 essential amino acids including, the branched - leucine, isoleucine, valine), marketed in different formulations, has already allowed to document a significant therapeutic efficacy in the treatment of elderly sarcopenic subjects. In fact, the use of these preparations improves physical performance and muscle strength by inducing the synthesis of proteins involved in the biogenesis and functionality of mitochondria - that is, the cellular organelles responsible for the production of energy in the form of ATP - and of myofibrillar proteins (which constitute the large percentage of muscle mass), both in laboratory animals and in humans.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sarcopenic Obesity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
After 1 week of standard diet (1650kcal/day with 18% protein) without physical activity, patients will be randomized into one of the 4 arms described below (20 subjects per study arm): 1st arm: low-calorie diet normoproteic with an energy deficit of 15% compared to what emerged from the calorimetric value (basal REE); 2nd arm: low-calorie diet normoproteic + an integration of 8.72 g of protein in the form of a nutritional supplement (18-20% protein; 3rd diet: low-calorie diet normoproteic + amino acid supplement (2 sachet/daily; 1 sachet contains protein 0 gr, carbohydrates 6.69 gr , lipids 0 gr, i-leucine 1,2 gr, i-isoleucine 0,6 gr, i-valine 0,6 gr). 4th diet: low-calorie diet normoproteic + an amino acid supplement (2 stick/daily; 1 stick pack contains protein 0 gr, carbohydrates 1,046 gr, lipids 0.074 gr, i-leucine 1.2 gr, i-isoleucine 0.6 gr, i-valine 0.6 gr, citric acid, succinic acid and malic acid). All patients perform daily aerobic physical activity/5 days/week for 4 weeks.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Diet Arm
Arm Type
Active Comparator
Arm Description
low-calorie diet normoproteic with an energy deficit of 15% compared to what emerged from the calorimetric value (basal REE)
Arm Title
Protein Arm
Arm Type
Active Comparator
Arm Description
low-calorie diet normoproteic + an integration of 8.72 g of protein in the form of a nutritional supplement (18-20% protein)
Arm Title
EAA Arm
Arm Type
Active Comparator
Arm Description
low-calorie diet normoproteic + amino acid supplement (2 sachet/daily; 1 sachet contains protein 0 gr, carbohydrates 6.69 gr , lipids 0 gr, i-leucine 1,2 gr, i-isoleucine 0,6 gr, i-valine 0,6 gr).
Arm Title
EAA + TCA
Arm Type
Active Comparator
Arm Description
low-calorie diet normoproteic + an amino acid supplement (2 stick/daily; 1 stick pack contains protein 0 gr, carbohydrates 1,046 gr, lipids 0.074 gr, i-leucine 1.2 gr, i-isoleucine 0.6 gr, i-valine 0.6 gr, citric acid, succinic acid and malic acid)
Intervention Type
Dietary Supplement
Intervention Name(s)
Diet + protein
Intervention Description
Comparison of the efficacy
Intervention Type
Dietary Supplement
Intervention Name(s)
Diet + EAA
Intervention Description
Comparison of the efficacy
Intervention Type
Dietary Supplement
Intervention Name(s)
Diet + EAA and TCA
Intervention Description
Comparison of the efficacy
Intervention Type
Other
Intervention Name(s)
Diet
Intervention Description
Comparison of the efficacy
Primary Outcome Measure Information:
Title
Change of Body weight
Description
weight in kilograms
Time Frame
basal and at 4 weeks
Title
Change of Height
Description
height in meters
Time Frame
basal and at 4 weeks
Title
Change of BMI
Description
weight and height will be combined to report BMI in kg/m^2
Time Frame
basal and at 4 weeks
Title
Change of Waist
Description
waist circumference in centimeters
Time Frame
basal and at 4 weeks
Title
Change of FM
Description
Fat Mass (FM) in % of body weight in kilograms
Time Frame
basal and at 4 weeks
Title
Change of FFM
Description
Free Fat Mass (FFM) in % of body weight in kilograms
Time Frame
basal and at 4 weeks
Title
Change of MM
Description
Muscle Mass (MM) in % of body weight in kilograms
Time Frame
basal and at 4 weeks
Title
Change of Muscle strenght
Description
muscle streght at the hand (right and left) in kg
Time Frame
basal and at 4 weeks
Title
Change of Walking
Description
6 minute walk test (6MWT), meters walking in 6 minutes
Time Frame
basal and at 4 weeks
Title
Change of TUG
Description
time, in second, to up from the chair, walks 3 meters, turns around, walks back to the chair and sits down
Time Frame
basal and at 4 weeks
Title
Change of Metabolic profile
Description
glycaemia, total cholesterol, LDL cholesterol, triglycerides all in mg/dl
Time Frame
basal and at 4 weeks
Title
Change of Insulin secretion
Description
insulin pasma levels in mU/l
Time Frame
basal and at 4 weeks
Title
Change of Homa index
Description
glycaemia and insulin will be combined to report Homa index in mmol/l/mU/l
Time Frame
basal and at 4 weeks
Title
Change of Muscle function
Description
irisin and procollagen type III N-terminal peptide (P3NP) in ng/ml
Time Frame
basal and at 4 weeks
Title
Change of Muscle wasting
Description
C-terminal agrin fragment (CAF) in pg/ml
Time Frame
basal and at 4 weeks

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients with obesity (BMI> 35kg / m2) sarcopenia (criteria described in Coltorti A et al). Exclusion Criteria: renal insufficiency diabetes muscular pathologies neurological-neurodegenerative pathologies cognitive decline
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amelia Brunani, MD
Organizational Affiliation
Istituto Auxologico Italiano
Official's Role
Principal Investigator
Facility Information:
Facility Name
Amelia Brunani
City
Verbania
State/Province
VB
ZIP/Postal Code
28921
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31505890
Citation
Hsu KJ, Liao CD, Tsai MW, Chen CN. Effects of Exercise and Nutritional Intervention on Body Composition, Metabolic Health, and Physical Performance in Adults with Sarcopenic Obesity: A Meta-Analysis. Nutrients. 2019 Sep 9;11(9):2163. doi: 10.3390/nu11092163.
Results Reference
background
PubMed Identifier
17702878
Citation
Wang X, Miller GD, Messier SP, Nicklas BJ. Knee strength maintained despite loss of lean body mass during weight loss in older obese adults with knee osteoarthritis. J Gerontol A Biol Sci Med Sci. 2007 Aug;62(8):866-71. doi: 10.1093/gerona/62.8.866.
Results Reference
background
PubMed Identifier
18580399
Citation
Frimel TN, Sinacore DR, Villareal DT. Exercise attenuates the weight-loss-induced reduction in muscle mass in frail obese older adults. Med Sci Sports Exerc. 2008 Jul;40(7):1213-9. doi: 10.1249/MSS.0b013e31816a85ce.
Results Reference
background
PubMed Identifier
28539168
Citation
Malafarina V, Uriz-Otano F, Malafarina C, Martinez JA, Zulet MA. Effectiveness of nutritional supplementation on sarcopenia and recovery in hip fracture patients. A multi-centre randomized trial. Maturitas. 2017 Jul;101:42-50. doi: 10.1016/j.maturitas.2017.04.010. Epub 2017 Apr 22.
Results Reference
background
PubMed Identifier
21636183
Citation
Rondanelli M, Opizzi A, Antoniello N, Boschi F, Iadarola P, Pasini E, Aquilani R, Dioguardi FS. Effect of essential amino acid supplementation on quality of life, amino acid profile and strength in institutionalized elderly patients. Clin Nutr. 2011 Oct;30(5):571-7. doi: 10.1016/j.clnu.2011.04.005. Epub 2011 Jun 1.
Results Reference
background
PubMed Identifier
20889128
Citation
D'Antona G, Ragni M, Cardile A, Tedesco L, Dossena M, Bruttini F, Caliaro F, Corsetti G, Bottinelli R, Carruba MO, Valerio A, Nisoli E. Branched-chain amino acid supplementation promotes survival and supports cardiac and skeletal muscle mitochondrial biogenesis in middle-aged mice. Cell Metab. 2010 Oct 6;12(4):362-372. doi: 10.1016/j.cmet.2010.08.016.
Results Reference
background
PubMed Identifier
18514630
Citation
Solerte SB, Gazzaruso C, Bonacasa R, Rondanelli M, Zamboni M, Basso C, Locatelli E, Schifino N, Giustina A, Fioravanti M. Nutritional supplements with oral amino acid mixtures increases whole-body lean mass and insulin sensitivity in elderly subjects with sarcopenia. Am J Cardiol. 2008 Jun 2;101(11A):69E-77E. doi: 10.1016/j.amjcard.2008.03.004.
Results Reference
background
PubMed Identifier
21566257
Citation
Valerio A, D'Antona G, Nisoli E. Branched-chain amino acids, mitochondrial biogenesis, and healthspan: an evolutionary perspective. Aging (Albany NY). 2011 May;3(5):464-78. doi: 10.18632/aging.100322.
Results Reference
background
PubMed Identifier
1944015
Citation
Coltorti A, Scalfi L, Borrelli R, Contaldo F, Diaz E. [Validity of 5 bioelectric impedance equations for the estimation of lean body mass in women]. Minerva Endocrinol. 1991 Jan-Mar;16(1):37-41. Italian.
Results Reference
background

Learn more about this trial

Nutritional Supplementation in Sarcopenic Obesity

We'll reach out to this number within 24 hrs